P1059 (10051): A Phase I Open-Label Study to Evaluate the Safety & Tolerability of Recombinant Vaccines in HIV-Infected Young Adults with Good Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy

Study Status Study Restriction


United States

What is P1059?

P1059 was Phase I, open-label study among HIV-infected youth receiving treatment in the United States.  The study was designed to determine the safety and tolerability of recombinant MVA and Fowlpox HIV-1 vaccines in HIV-1-infected young adults with good control of HIV replication (HIV RNA < 100 copies/mL for 6 months) on stable antiretroviral therapy.

Study documents:

Sites where the study was implemented:

CRS ID Site Name City Country
No sites at this time.

Study contacts:

No records returned.

CTS: IMPAACT Operations Center


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.